Silence Therapeutics bids farewell to group ceo

Published: 20-Aug-2008
Recruitment

Personal reasons have forced former group ceo Jeffery Vick of European RNAi biotech company Silence Therapeutics to step down from his role.


Personal reasons have forced former group ceo Jeffery Vick of European RNAi biotech company Silence Therapeutics to step down from his role.

He will be replaced by Iain Ross, currently non-executive chairman, full time chairman and group ceo. The board of directors has also appointed Jeremy Curnock Cook as senior independent non-executive director of the company. Cook said: "Iain Ross was responsible for the financial and operational turnaround of the company from July 2004 until July 2007 and the Silence Board of Directors is confident that under his executive leadership, significant shareholder value can be generated. Ross is an experienced business negotiator and we believe he can bring to fruition a number of deals and collaborations currently under discussion."

Ross, chairman & ceo, said: "I believe that by employing a more focused and aggressive approach, and with the continued support of a first class management team, we can achieve meaningful technical and commercial milestones over the next 12 months."

See more

You may also like

Recruitment

Rentschler Biopharma continues hiring at global sites

Read more
During 2021, the company has hired more than 300 employees across all business functions with a strong focus on production and laboratory personnel

Trending Articles

  1. hard to swallow...
  2. People on the Move US biotechnology company <i>La Jolla Pharmaceutical</i> has promoted <b>Gail Sloan</b> to vice president of finance, controller and secretary. Sloan has previously worked with Affymax Research Institute and Ernst & Young.
  3. Bioprogress appoint new position and restructure board <p>BioProgress, the speciality pharmaceutical and healthcare company, has announced the creation of a new executive operational board, and the appointment of Keith Hemming, as head of operations in a new position within the management team of the company.</p>
  4. Drug formulation and delivery expert Dr Joseph Reo appointed as Catalent’s Director of Global Scientific Affairs Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced the appointment of Dr Joseph (Joe) Reo to the role of Director of Global Scientific Affairs
  5. People on the move

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Recruitment

Rentschler Biopharma continues hiring at global sites

During 2021, the company has hired more than 300 employees across all business functions with a strong focus on production and laboratory personnel
Recruitment

Vetter Pharma invests $4.1m in Ravensburg training facility

The centre opened on September 14, with a small celebration held for management, training management and trainees.
Recruitment

Does pharma have a problem with inclusivity and innovation?

As we’ve seen only too clearly in recent weeks, the pharmaceutical industry is of paramount importance to the global economy and society. The collaboration regarding the COVID-19 pandemic is an example of the sector at its best, reports Stephen Frost, Founder, Frost Included
Recruitment

Cell Mogrify undergoes period of change

A cash injection and change in leadership gives momentum to the cell therapy company for direct cellular conversion platform
Recruitment

Novartis scoops Top Employer award

Novartis UK and its subsidiary, Sandoz, have been certified as ‘Top Employers’ of 2019 by Top Employers Institute
Recruitment

Retention, not just recruitment

Six ways to protect your company from the skills crisis
Recruitment

Particle Testing Authority (PTA) boosts company's thermal analysis capabilities

Particle Testing Authority (PTA), a division of Micromeritics Instrument Corporation, now has expanded thermal analysis capabilities with addition of Bryan Shaw to its team
Subscribe now